Technical Analysis for PRPO - Precipio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 5.68 | 0.00% | 0.00 |
Earnings due: May 15
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.99% | |
| Inside Day | Range Contraction | -4.99% |
| Alert | Time |
|---|---|
| Gap Down Closed | 1 day ago |
| 10 DMA Support | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Outside Day | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/15/2024
Precipio, Inc. Description
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Disease Natural Sciences Treatment Of Cancer Molecular Biology Genomics Molecular Diagnostics Laboratory Services Analytical Services Personalized Medicine Laboratory Techniques Polymerase Chain Reaction Pharmacogenomics Molecular Technologies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.99 |
| 52 Week Low | 0.2505 |
| Average Volume | 3,663 |
| 200-Day Moving Average | 5.25 |
| 50-Day Moving Average | 6.26 |
| 20-Day Moving Average | 6.16 |
| 10-Day Moving Average | 5.86 |
| Average True Range | 0.26 |
| RSI (14) | 40.12 |
| ADX | 19.23 |
| +DI | 18.06 |
| -DI | 25.71 |
| Chandelier Exit (Long, 3 ATRs) | 6.05 |
| Chandelier Exit (Short, 3 ATRs) | 6.40 |
| Upper Bollinger Bands | 6.95 |
| Lower Bollinger Band | 5.38 |
| Percent B (%b) | 0.19 |
| BandWidth | 25.43 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.13 |
| MACD Histogram | -0.0473 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.68 | ||||
| Resistance 3 (R3) | 5.68 | 5.68 | 5.68 | ||
| Resistance 2 (R2) | 5.68 | 5.68 | 5.68 | 5.68 | |
| Resistance 1 (R1) | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 |
| Pivot Point | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 |
| Support 1 (S1) | 5.68 | 5.68 | 5.68 | 5.68 | 5.68 |
| Support 2 (S2) | 5.68 | 5.68 | 5.68 | 5.68 | |
| Support 3 (S3) | 5.68 | 5.68 | 5.68 | ||
| Support 4 (S4) | 5.68 |
